MedMira Receives FDA Approval for HIV Test Enhancements

MedMira, a company specializing in rapid flow-through diagnostic technology, announced it has received approval from the FDA to provide new features in its Reveal G2 Rapid HIV-1 Antibody Test.

This latest FDA approval enables MedMira to provide external control material with an extended shelf-life and additional flexibility. MedMira's enhancement to the external controls are thought to improve cost-effectiveness and versatility for the customer.

MedMira's Reveal G2 rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. The test is currently the fastest rapid HIV test, at only three minutes, available in the U.S.